The bill
Protect Infant Formula from Contamination Act
S. 272, 119th Congress — read as touching Pharmaceuticals.
Sponsored by
Sen. Peters, Gary C. [D-MI]
ID: P000595
Follow the money
The bill
S. 272, 119th Congress — read as touching Pharmaceuticals.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
30 itemised contributions to this sponsor, pulled from FEC filings.
The alignment
This bill's text tracks the "Department of Health and Human Services" section, p. 488-490 of the Mandate for Leadership.
Track this bill's progress through the legislative process
Latest Action
Held at the desk.
May 3, 2026
📍 Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Joy, another congressional bill that's about as effective as a Band-Aid on a bullet wound. Let's dissect this mess, shall we?
**Main Purpose & Objectives:** The Protect Infant Formula from Contamination Act (S 272) claims to improve the safety of infant formula by testing for microorganisms and implementing corrective actions. How noble. I'm sure it has nothing to do with the fact that there have been recent high-profile recalls and the manufacturers are sweating bullets.
**Key Provisions & Changes to Existing Law:** The bill amends the Federal Food, Drug, and Cosmetic Act to require infant formula manufacturers to notify the Secretary of Health and Human Services within 1 business day if they detect any microorganisms in their products. Oh, wow, a whole business day? That's lightning-fast response time. It also requires the Secretary to respond within 1 business day and work with the manufacturer to investigate and take corrective action. Because, you know, the FDA hasn't been doing that already.
**Affected Parties & Stakeholders:** The usual suspects: infant formula manufacturers, the FDA, Congress (who get to pretend they're doing something useful), and parents who actually care about their babies' health. But let's be real, this bill is primarily designed to protect the interests of the manufacturers and the politicians who take their money.
**Potential Impact & Implications:** This bill is a classic case of "too little, too late." It's a Band-Aid on a festering wound. The real issue is the lack of regulation and oversight in the infant formula industry, which has led to numerous recalls and safety issues. This bill doesn't address the root causes; it just adds more bureaucratic red tape. The manufacturers will continue to prioritize profits over safety, and the FDA will still be understaffed and underfunded.
In conclusion, this bill is a farce. It's a PR stunt designed to make Congress look like they're doing something about infant formula safety while actually doing nothing to address the underlying problems. The real disease here is corruption and greed, and this bill is just a symptom of a larger illness. Wake me up when they actually pass meaningful legislation that prioritizes public health over corporate interests.
Sen. Peters, Gary C. [D-MI]
Congress 119 • 2024 Election Cycle
No PAC contributions found
No committee contributions found
This bill has 9 cosponsors. Below are their top campaign contributors.
ID: H001061
Top Contributors
24
ID: C001035
Top Contributors
21
ID: S001203
Top Contributors
34
ID: S001181
Top Contributors
21
ID: H001076
Top Contributors
20
ID: K000384
Top Contributors
30
ID: B001230
Top Contributors
72
ID: M001111
Top Contributors
35
ID: F000463
Top Contributors
27
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 52 nodes and 74 connections
Total contributions: $74
Showing top 18 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 1 harmed.
Section 2 amends the Federal Food, Drug, and Cosmetic Act to require infant formula manufacturers to notify the Secretary within 1 business day of a confirmed positive analytical result for microorganisms, consult with the Secretary, cease distribution, dispose of affected product, and provide results and isolates or genome sequence data. Section 3 adds reporting requirements including progress reports, quarterly supply chain reports, consultation with USDA, and reports on adequacy of supply. Th
For each industry this bill affects, here's what the sponsor (Sen. Peters, Gary C. [D-MI])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.
This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.
AI Analysis:
"Both the bill and the Project 2025 excerpt involve HHS/FDA oversight and aim to improve public health safety, but the bill focuses on infant formula contamination while the Project 2025 sections address abortion data, generic drugs, laboratory-developed tests, drug shortages, and abortion pills, resulting only a tangential connection."
— 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11 — 457 — Department of Health and Human Services The “laboratory-developed tests” category currently encompasses a range of possible tests, many of which would be characterized more appropriately as “lab- oratory-modified tests” because they are not truly novel tests but rather modified versions of existing tests. To avoid stifling innovation and access to medical care, the applicable statutes and regulations should be revised to facilitate greater access to such modified tests.12 Finally, the FDA has long held that it has regulatory authority over such tests, while others have argued that they should be considered clinical services regulated by the Centers for Medicare and Medicaid Services (CMS). The FDA currently has regulatory authority over in vitro diagnostics, and under the Clinical Lab- oratory Improvement Amendments (CLIA),13 the CMS ensures that labs meet analytical validity standards for test methods. Congress, the FDA, and the CMS need to clarify and disentangle overlapping authorities over tests to eliminate regulatory confusion.14 Drug Shortages. The very thin profit margins and the regulatory burdens associated with generic drug manufacturing discourage inventory and capacity investments by manufacturers and contribute to drug shortages. HHS and the FDA should encourage more dependable generic drug manufacturing. The FDA should expand its current pass/fail approach to drug facility inspec- tions into a graded system that recognizes manufacturers that exceed minimum standards by investing in improving production reliability. The FDA should also add facility codes to drug packaging and construct a searchable database that cross-references product codes and facility codes. That would enable wholesalers and pharmacy benefit managers to identify and preference drugs manufactured at more reliable facilities, thus encouraging generic drug manufacturers to compete on reliability as well as on price. For its part, HHS should exempt multi-source generic drugs from requirements to pay rebates to Medicaid and other federally funded health programs, as those provisions penalize new investments in expanding manufacturing capacity when supply is unable to meet demand.15 Additionally, FDA and NIH should promote efficacy trials of new applications for generic drugs, which might include NIH fund- ing such trials or conducting its own. Abortion Pills. Abortion pills pose the single greatest threat to unborn chil- dren in a post-Roe world. The rate of chemical abortion in the U.S. has increased by more than 150 percent in the past decade; more than half of annual abortions in the U.S. are chemical rather than surgical. The abortion pill regimen is typically a two-part process. The first pill, mifepris- tone, causes the death of the unborn child by cutting off the hormone progesterone, which is required to sustain a pregnancy. The second pill, misoprostol, causes con- tractions to induce a delivery of the dead child and uterine contents, usually into a toilet at home. The abortion-pill regimen is currently approved for up to 70 days
AI Analysis:
"The bill focuses on domestic safety testing, notification, and corrective actions for infant formula, while Project 2025’s Trade section advocates liberalizing imports, reducing tariffs, and mutual recognition to diversify supply chains. Both concern infant formula supply chain resilience, but the bill does not implement the trade‑policy recommendations."
— 807 — Trade Supply Chain Lessons from the Baby Formula Debacle. Protectionism builds weaknesses into supply chains. This was demonstrated vividly by the baby formula shortage, which may have peaked in 2022 but remains an ongoing concern. Domestic baby formula producers benefit from a decades-old tariff that averages 17 percent, which is effectively high enough to shut imports out of the market. As if tariffs were not enough, other requirements also help to keep competition out of the market: ever-evolving labeling requirements and nutritional standards that (conveniently for domestic manufacturers) are always just slightly different from international standards. As a result, before the formula shortage in 2022, approx- imately 98 percent of the country’s baby formula was produced domestically. With foreign competition out of the way, other government policies helped to concentrate almost the entire domestic formula industry into four firms. Roughly 40 percent of baby formula purchases are made by state-level food assistance pro- grams, which typically do not let families choose their own formula brands. Instead they must buy from a single producer, which guarantees producers large market shares in states where they win contracts. This situation gives incumbent pro- ducers a cozy existence but puts consumers at risk. Like all protectionist policies, the benefits are concentrated in the hands of a few producers while the costs and risks are widely distributed. With so many eggs in so few baskets, whenever something goes wrong—which is inevitable even when nobody is at fault—families find themselves scrambling. That happened early in 2022 when contamination entered a Michigan facility that makes about 40 percent of America’s baby formula. Trade protectionism all but eliminated other options for many parents, who suddenly found empty shelves and sky-high prices for an essential item that many of them were already struggling to afford—while families in other countries were unaffected. In response, Congress passed the Formula Act68 in the summer of 2022. The act eased formula tariffs and loosened never-needed labeling requirements and other import restrictions, but it was temporary. It expired at the end of 2022, leaving families still vulnerable to the cascading consequences that ensue if one thing goes wrong at only one plant. The baby formula debacle has two lessons for the next Administration. l The Administration needs to attack the root of the problem. Temporary fix-it bills are better than nothing, but they leave the rot in place. The President needs to encourage bold liberalization. l Strength comes from openness. In the real world, markets fail. Factories will get contaminated, and health inspectors will not always be as thorough as they should be. The baby formula market is essentially a natural experiment in self-sufficient industrial policy. When something went wrong, that single — 808 — Mandate for Leadership: The Conservative Promise failure point crashed the whole system. It should not be that way, and the next President can change it. Part of the problem is that the supply chain analogy itself causes sloppy thinking. In a chain, a link is connected only to the link ahead of it and the link behind it and not to any other links. Real-world supply chains are more like networks in which each point connects directly to countless others and is rarely more than six degrees of separation from nearly anywhere on Earth. Because market failures happen all the time, it is important to have as many connections as possible. Americans need access to more ways to adapt and reroute around failure points, especially for essential products like baby formula. Trade protectionism makes us more vulnerable, but free trade makes our fam- ilies and communities more resilient. Loosening restrictions similar to the ones that stunt the baby formula market would make it easier to navigate future crises while preventing the progressive and rent-seeking power grabs that come with every crisis, whether it is as isolated as a baby formula shortage or as expansive as a pandemic. Mutual Recognition. A simple way to reduce friction in supply networks is mutual recognition of other industrialized countries’ regulatory standards. This can be done either in a larger trade agreement or independently. For baby for- mula, this would mean allowing in brands that meet European Union standards even if they do not meet Food and Drug Administration (FDA) labeling require- ments. Infants’ nutritional needs do not change across borders. If a formula is deemed healthy for European babies, then it is also healthy for American babies. The reverse is equally true. Mutual recognition could help to open new markets for American producers in countless industries and give American consumers access to countless new prod- ucts on more competitive terms. For example, U.S. regulations require washing machine power cords to be at least six feet long, while the U.K. requires them to be at least two meters.69 The difference (about six inches) affects neither safety nor performance, but it does keep American-made washing machines out of an import- ant foreign market. A mutual recognition policy would circumvent the problem. Given the recent interest in increased antitrust enforcement, conservatives should embrace policies like mutual recognition that have the double benefit of increasing market competition while decreasing government’s regulatory footprint. The U.S. should enact mutual recognition agreements for a wide variety goods with the United Kingdom, European Union, Japan, South Korea, Australia, and other governments with high standards comparable to our own. This would have especially large benefits for pharmaceuticals, because America’s FDA drug approval process is both slower and more expensive than those of other countries with- out being any safer. Americans would gain access to more and lower-cost medical
AI Analysis:
"The bill focuses on enhancing safety testing and rapid response to contamination, while Project 2025’s trade section advocates reducing protectionist tariffs and labeling barriers to diversify supply; both address infant formula supply chain resilience but target different mechanisms."
— 807 — Trade Supply Chain Lessons from the Baby Formula Debacle. Protectionism builds weaknesses into supply chains. This was demonstrated vividly by the baby formula shortage, which may have peaked in 2022 but remains an ongoing concern. Domestic baby formula producers benefit from a decades-old tariff that averages 17 percent, which is effectively high enough to shut imports out of the market. As if tariffs were not enough, other requirements also help to keep competition out of the market: ever-evolving labeling requirements and nutritional standards that (conveniently for domestic manufacturers) are always just slightly different from international standards. As a result, before the formula shortage in 2022, approx- imately 98 percent of the country’s baby formula was produced domestically. With foreign competition out of the way, other government policies helped to concentrate almost the entire domestic formula industry into four firms. Roughly 40 percent of baby formula purchases are made by state-level food assistance pro- grams, which typically do not let families choose their own formula brands. Instead they must buy from a single producer, which guarantees producers large market shares in states where they win contracts. This situation gives incumbent pro- ducers a cozy existence but puts consumers at risk. Like all protectionist policies, the benefits are concentrated in the hands of a few producers while the costs and risks are widely distributed. With so many eggs in so few baskets, whenever something goes wrong—which is inevitable even when nobody is at fault—families find themselves scrambling. That happened early in 2022 when contamination entered a Michigan facility that makes about 40 percent of America’s baby formula. Trade protectionism all but eliminated other options for many parents, who suddenly found empty shelves and sky-high prices for an essential item that many of them were already struggling to afford—while families in other countries were unaffected. In response, Congress passed the Formula Act68 in the summer of 2022. The act eased formula tariffs and loosened never-needed labeling requirements and other import restrictions, but it was temporary. It expired at the end of 2022, leaving families still vulnerable to the cascading consequences that ensue if one thing goes wrong at only one plant. The baby formula debacle has two lessons for the next Administration. l The Administration needs to attack the root of the problem. Temporary fix-it bills are better than nothing, but they leave the rot in place. The President needs to encourage bold liberalization. l Strength comes from openness. In the real world, markets fail. Factories will get contaminated, and health inspectors will not always be as thorough as they should be. The baby formula market is essentially a natural experiment in self-sufficient industrial policy. When something went wrong, that single
Showing 3 of 5 policy matches
Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.